These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 32683679)

  • 1. Liquid biopsies: Potential and challenges.
    Heidrich I; Ačkar L; Mossahebi Mohammadi P; Pantel K
    Int J Cancer; 2021 Feb; 148(3):528-545. PubMed ID: 32683679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Significance of Circulating Tumour Cells in the Clinic.
    Abalde-Cela S; Piairo P; Diéguez L
    Acta Cytol; 2019; 63(6):466-478. PubMed ID: 30820013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of liquid biopsies in colorectal cancer.
    Wills B; Gorse E; Lee V
    Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers.
    Addanki S; Meas S; Sarli VN; Singh B; Lucci A
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid biopsy in prostate cancer: A novel dual biomarker analysis approach integrating circulating tumor cells and circulating tumor DNA data.
    Li Q; Tang L; Zhao Y; Li Z; Ma W; Ma L
    Cell Mol Biol (Noisy-le-grand); 2024 Sep; 70(8):158-163. PubMed ID: 39262247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid biopsy: novel technologies and clinical applications.
    Reimers N; Pantel K
    Clin Chem Lab Med; 2019 Feb; 57(3):312-316. PubMed ID: 30465714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
    Croessmann S; Park BH
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring.
    Tao XY; Li QQ; Zeng Y
    Mol Cancer; 2024 Jul; 23(1):145. PubMed ID: 39014366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer.
    Germano G; Mauri G; Siravegna G; Dive C; Pierce J; Di Nicolantonio F; D'Incalci M; Bardelli A; Siena S; Sartore-Bianchi A
    Clin Colorectal Cancer; 2018 Mar; 17(1):80-83. PubMed ID: 29195807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Application of Liquid Biopsies in Metastatic Prostate Cancer.
    Morrison GJ; Goldkorn A
    Curr Oncol Rep; 2018 Mar; 20(4):35. PubMed ID: 29572775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fundamentals of liquid biopsies in metastatic prostate cancer: from characterization to stratification.
    van Dessel LF; Martens JWM; Lolkema MP
    Curr Opin Oncol; 2020 Sep; 32(5):527-534. PubMed ID: 32675591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
    Haupts A; Roth W; Hartmann N
    Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.
    Zhang X; Ju S; Wang X; Cong H
    Clin Exp Med; 2019 Aug; 19(3):271-279. PubMed ID: 31190187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.